We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Quigley Corporation, the leading developer and marketer of diversified health products, anounced that its whollyowned Quigley Pharma (Ethical Pharmaceuticals) subsidiary has obtained results from its continued preclinical research on QR440 -- a botanical broad-spectrum anti-inflammatory compound -- which show that QR440 may have disease-modifying potential.
Computer Sciences has announced that DVC LLC, a CSC company, has entered into a Phase I clinical trial for its Venezuelan equine encephalitis (VEE) vaccine candidate V3526.
Adherex Technologies, a biopharmaceutical company with a broad portfolio of oncology products under development, has initiated two additional sites for its Phase II clinical trial of ADH-1 (Exherin): Princess Margaret Hospital in Toronto and Jewish General Hospital in Montreal.
King Pharmaceuticals and Palatin Technologies have initiated patient enrollment in two double- blind, placebo-controlled Phase IIb clinical trials of the drug PT-141 in patients with erectile dysfunction (ED).
Isotechnika announced that the Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247, continues to demonstrate a promising safety and efficacy profile.
BioMarin Pharmaceutical announced that it has submitted a New Drug Application to FDA for Orapred ODT (prednisolone sodium phosphate orally disintegrating tablets), a new formulation of Orapred (prednisolone sodium phosphate oral solution).
Amgen and Abgenix have announced that the FDA has granted fast-track designation for panitumumab, an experimental fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr), for patients with metastatic colorectal cancer who have failed standard chemotherapy treatment.
The results of an international clinical trial led by Duke University Medical Center researchers has shown that a new drug is not a suitable replacement for protamine, a drug that has been used for more than 40 years after coronary artery bypass surgery to return thinned blood to its normal state.
Transition Therapeutics Inc. has announced that patient enrollment has commenced for a Phase I/II clinical trial of its Interferon Enhancing Therapy, HCV-I.E.T.
MediciNova has begun enrolling patients in a Phase II clinical study with MN-166 for the treatment of multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system.